Educated 30-45-year-old professionals who have already failed SSRIs, CBT, and other conventional treatments and are now actively researching or paying out-of-pocket for psilocybin, MDMA, or ketamine therapy to resolve persistent PTSD, treatment-resistant depression, or severe anxiety. Insurance covers almost none of it, so they spend $3,000-$20,000+ per treatment cycle — and the support layer around preparation, vetting, and integration is almost entirely unbuilt.
On April 18, 2026, President Trump signed an executive order fast-tracking FDA review of psychedelic therapies and allocating $50 million in federal funds — the first White House-level signal that drives mainstream patient awareness and reduces stigma overnight, pulling millions of treatment-resistant patients off the fence (White House, April 2026).
The psychedelic-assisted therapeutics market hit $6.28 billion in 2026 and is growing at a 14-16% CAGR toward $18+ billion by 2034 — sustained double-digit growth this fast means new buyers are entering every quarter, not just existing buyers spending more (ResearchIntelo / Research and Markets, 2026).
Compass Pathways filed a rolling NDA for COMP360 psilocybin targeting Q4 2026, with FDA priority review vouchers compressing the timeline to 1-2 months — an imminent first-ever classic psychedelic FDA approval will trigger a massive wave of newly eligible patients who need vetted therapist lists, preparation guides, and integration coaching before and after their first session (Medical Daily / Top Doctor Magazine, June/May 2026).
The exact words they type into Google.
Create a free account to unlock the full breakdown — all 3 ideas and every community map on the site.
Free forever. No credit card. Takes 20 seconds.